JPH0984877A - Intracatheter - Google Patents

Abstract

PROBLEM TO BE SOLVED: To realize a new coronary blood circulation reconstructive surgery for reinforcing even a vascular wall of brittle and weak coronary arterioselerotic disease together with dissociation and thrombus by forming the first and second balloons with a synthetic resin which does not react with a coagulating agent. SOLUTION: A first balloon 20 is arranged on the outer peripheral part of a catherer main body part 10 of a catheter apex part and is expanded by injecting an expanding material into an injection cavity between the main body part 10 and this balloon 20 from an injection port of the catheter. An adhesive can be stored and held liq.-tightly from outside in the second balloon 30 provided on a part of the outer peripheral part (the central part of the outer peripheral part) of the first balloon 20 and a specified number of micropores are arranged in the central part in the second balloon 30 in such a way that the adhesive oozes out. In addition, the first and second balloons 20, 30 are formed of a synthetic resin which does not react with a coagulating agent.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an intravascular catheter, and more particularly to an intravascular catheter capable of administering a therapeutic agent only to a desired site in a blood vessel or suitable for percutaneous coronary angioplasty.

[0002]

2. Description of the Related Art Percutaneous coronary angioplasty (PTCA) has become widespread and almost established as an excellent coronary revascularization technique for ischemic heart disease.

However, in a fragile arteriosclerotic lesion accompanied by dissociation, ulcer, thrombus, etc., acute coronary occlusion can often occur during PTCA. This acute coronary occlusion is due to the recently developed stent, DCA (Directional Co).
With the advent of so-called new tools, such as the Ronary Angioplasty), it has become detached in some cases.

[0004]

However, even if the above-mentioned device is used, the formation of thrombus or dissociation may not be prevented, which may lead to the progress thereof, which is a problem that has not been completely solved. . The coronary disease morbidity of the Japanese is increasing year by year, and it is expected that the role played by PTCA will become more important in the future, and there is an urgent need to completely solve this problem.

Therefore, it has been desired to develop a tool and method for eliminating dissociation and thrombus that cause acute coronary occlusion.

[0006]

The present invention solves the above-mentioned problems, and can realize a new coronary revascularization technique that reinforces the dissection and thrombus even in the vascular wall of a fragile coronary atherosclerotic lesion. The present invention is made for the purpose of providing an intravascular catheter, and has the following configuration as one means for achieving the above-mentioned object.

That is, in the vicinity of the tip of an intravascular catheter to be inserted into a blood vessel of a living body, a first balloon capable of injecting an expanding material for expanding the blood vessel therein, and at least a part of the first balloon. A second outer wall having an outer wall permeable to the outside capable of injecting or holding an anticoagulant coagulant that reinforces a blood vessel wall between the first balloon and the first balloon And a balloon, wherein the first balloon and the second balloon are made of a synthetic resin that does not react with the coagulant.

Further, for example, the second balloon is formed of a permeable membrane having a unidirectional permeation property from the inner side to the outer side. Alternatively, a coagulant is previously held in a liquid-tight state between the first balloon and the second balloon, and when the first balloon is expanded at the treatment site, the coagulant is permeated to the outside from the second balloon. , Reinforcing the inner wall of the blood vessel.

Further, for example, the second balloon is pressurized by the expansion of the first balloon to allow the coagulant to penetrate into the blood vessel.

Alternatively, a first balloon capable of injecting an expanding material for expanding a blood vessel into a tip portion of an intravascular catheter to be inserted into a blood vessel of a living body, and at least a part of an outer circumference of the first balloon. A second balloon having at least a part of an outer wall capable of injecting or holding a therapeutic agent between the first balloon and the held portion, the outer wall being capable of penetrating the outside to the outside. It has a long shape and is characterized in that the front and back are formed in a gentle hill shape when expanded.

Further, for example, the second balloon is formed of a permeable membrane having a unidirectional permeation characteristic from the inner side to the outer side. Further, for example, the therapeutic agent is held in a liquid-tight state in advance between the first balloon and the second balloon, and when the first balloon is expanded at the treatment site, it is pressurized by the expansion of the first balloon. The treatment is performed by infiltrating a therapeutic agent into the inner part of the second balloon, which has a projecting shape like a hill.

[0012]

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, an embodiment of the present invention will be described in detail with reference to the drawings.

[First Example of Embodiment of the Invention] The inventor of the present application has proposed a new coronary revascularization method in which a vascular wall of a fragile coronary atherosclerotic lesion is solidified in a tunnel shape with an adhesive together with a dissociation or a thrombus to reinforce it. He invented surgery and developed a vascular catheter suitable for realizing this.

A blood vessel catheter which is an example of an embodiment of the invention according to the present invention, which is suitable for this new coronary revascularization operation, has the following configuration. That is, the distal end portion of the blood vessel catheter has a double-balloon structure, the inside of the first paloon is used for expansion, and the space between the first balloon and the second balloon is used for a coagulant. Then, from the injection port of the catheter, the injection cavity between the first balloon and the second balloon, that is, the outermost lumen (oute).
It is configured such that the coagulant injected into the (r lumen) exudes to the surface of the outer second balloon. In this example, an adhesive (liquid) whose details will be described later is used as the coagulant.

Then, at the time of PTCA, an adhesive having an antithrombotic property is injected between the second balloon and the first balloon, and when the first balloon is expanded at the expansion target site in the blood vessel, it is added to this injection pressure, The expansion pressure of the first balloon causes the adhesive to exude to the outside of the second balloon, instantly solidifying the fragile vascular wall that is easily collapsed together with the lesion, and reinforcing it in a tunnel shape.

In other words, it is a method in which a synthetic resin stent having antithrombogenicity is instantly formed in a lesion.

The coronary revascularization technique using such an adhesive has been unprecedented in Japan and abroad and is extremely original. As a result, the bioadhesive suitable for use in the coronary revascularization and the vascular catheter of this example for locally reaching the lesion also have an original structure. . The principle of the blood vessel catheter of this example will be described below with reference to FIG.

FIGS. 1 and 2 show the structure of the blood vessel catheter (PTCA catheter) of this example. FIG. 1 shows the catheter distal end before balloon expansion.
FIG. 2 shows the state after balloon expansion.

In the figure, reference numeral 10 is a catheter main body portion of the catheter tip portion, and 20 is a first balloon disposed on the outer peripheral portion of the catheter main body portion 10. From the injection port of the catheter, the main body portion 10 and the first balloon are provided. The first balloon 20 is expanded by injecting the expansion material into the injection cavity between the balloons 20. As the expansion material, it is desirable to use a blood vessel contrast agent, for example. As a result, the work can be performed while easily visually confirming the position of the blood vessel where the catheter tip portion is located.

Reference numeral 30 is a second balloon provided on a part of the outer periphery of the first balloon 20 (center of the outer periphery),
This is a second balloon capable of liquid-tightly containing and holding the adhesive from the outside. The outer diameter of the second balloon 30 is substantially determined by the diameter of the blood vessel to be used. For example, the diameter is 2 mm to 3 mm.
There are things like. Even if this diameter is different, there is no difference in the basic structure and usage.

The second balloon 30 is provided with a predetermined number of micropores at a central portion over a length of 10 mm so that the adhesive may exude. The diameter of this micropore is
Although it depends on the viscosity of the adhesive, it has an optimal diameter so that the adhesive does not seep out from the inside and blood or the like does not inadvertently flow from the outside. Specifically, the diameter is several hundreds of microns or less, and micropores having a diameter of about 200 to 300 microns are arranged.

The adhesive injected from the injection port into the injection cavity between the first balloon 20 on the inner side and the second balloon 30 on the outer side is applied to the surface of the second balloon 30 by the aforementioned micropores. More exuded.

As shown in FIG. 1 before expansion, the first balloon 20 has an outer diameter substantially the same as that of the main body portion 10 before expansion, but the first balloon 30 after expansion shown in FIG. When the expansion material is injected into the inside, the first balloon 20 expands, and the second balloon 30 is pressed against the target expansion site of the blood vessel wall.
If the adhesive is injected into the second balloon 30 in this state, the adhesive oozes out from the above-mentioned micropores of the second balloon as indicated by 300 in FIG.

Reference numeral 40 denotes an adhesive holding portion connected to an injection port connected to the injection cavity between the first balloon 20 and the second balloon 30 of the catheter, which has a liquid-tight structure. Then, a desired amount of the adhesive is injected into the second balloon 30 by operating the pressure lever of the injection section.

Reference numeral 50 denotes a dilatation pressurizing unit, which is connected to, for example, an injection port for holding the above-mentioned dilatation material (vascular contrast agent or the like) and connecting it to the injection cavity in the first balloon 20. The desired amount of expansion material is infused into the first balloon 20. The adhesive used in this example having the above configuration will be described below. The adhesive used here is ideal if it satisfies the following items.

1) The adhesive ability is maintained even in the presence of blood. 2) Promptly adhere in vivo. 3) Biotoxicity is acceptable. 4) There is little foreign body reaction. 5) Sterilization is possible. 6) It has antithrombotic properties. 7) Does not solidify in the delivery system, including holding tanks and catheters. 8) It has flexibility.

In the present example, surgical cyanoacrylate (α-cyanoacrylate) was selected from among the existing bioadhesives as one that substantially satisfies these conditions. As α-cyanoacrylate, surgical Aron Alpha A manufactured by Sankyo is commercially available and can be used. Note that this commercially available product is not for the above-mentioned applications and has a slightly low flexibility, and therefore it is desirable to use a product having higher flexibility and higher viscosity. Then, it is desirable that the coagulation time can be adjusted by the expansion site, and in order to prevent coagulation at other than the target site, a plurality of solvents may be mixed and coagulated at the target site at the time of use. good.

Using the catheter of this example, coagulation of the blood vessel wall at the target expansion site when α-cyanoacrylate was used as an adhesive was performed under the following conditions, and its effectiveness was confirmed. The subjects were bilateral femoral arteries of adult goats in terms of examination of blood vessel diameter and ease of experimental diameter. The balloon diameter of the catheter used was 2.5 mm or 3.0 mm depending on the blood vessel diameter.

Under general anesthesia, the bilateral femoral arteries of the adult goat were exposed, and then a vascular catheter was directly inserted into the blood vessel from the distal side of the femoral artery. Then, the first balloon 2 at the expansion target site
0 is expanded at low pressure of 4 atm using physiological saline,
Further inject α-cyanoacrylate from the injection port,
It was applied to the inner wall of the blood vessel. Immediately after that, the first balloon 20
Was expanded at 6 atm and left for 3-10 minutes.

After the balloon deflation, the catheter was removed, and the ejection of blood flow from the catheter insertion hole of the femoral artery was confirmed. The blood vessel at the dilated site was cut out, fixed and stained, and the tissue sample was examined with an optical microscope.

1. Results of examination of adhesives. As a result of this study, α-cyanoacrylate is favorably
Exuded to the outside of the balloon 30. The α-cyanoacrylate attached to the outside of the second balloon of the catheter did not coagulate and could be easily removed with dry gauze. After wiping off, the mixture was left at room temperature for about 1 hour, but the α-cyanoacrylate in the catheter did not solidify, and when the injection pressure was applied again, the α-cyanoacrylate exudes again to the outside of the balloon. A priming volume of about 0.4 ml was required before the α-cyanoacrylate began to bleed to the outside of the balloon.

As a result, it was confirmed that α-cyanoacrylate can be used as an adhesive in this case.

2. Results of Acute Animal Experiments As a result of conducting experiments on a total of 6 bilateral femoral arteries of 3 adult goats, about 0.04 ml of α-cyanoacrylate injected into the blood vessel of 3 rats was examined. Succeeded in forming a hard solidified tunnel. After removal of the catheter, better blood flow was observed from the catheter insertion hole, and reperfusion was obtained. α-cyanoacrylate begins to solidify in about 5 seconds after injection,
I tried to feel it from the outside of the blood vessel, but the completed tunnel was quite stiff.

FIG. 3 shows a schematic diagram of the repair situation of the blood vessel wall based on the results of the above experiments. (1) of FIG. 3 shows a vascular wall of a fragile coronary atherosclerotic lesion which is a target expansion site before repair,
(2) shows a state in which the catheter of this example is inserted and positioned at this target expansion site, and injection of an adhesive and expansion of the balloon are started. The adhesive is applied from the micropores provided on the surface of the second balloon 30. The exuding state is schematically shown. Further, (3) of FIG. 3 shows a state where the application of the adhesive is completed and the repair is completed.

As shown in (3) of FIG. 3, a state in which the adhesive is strongly adhered to the inner wall of the blood vessel by applying the adhesive to the blood vessel wall of the fragile coronary atherosclerotic lesion using the catheter for blood vessel of this example Thus, a translucent α-cyanoacrylate tunnel layer can be formed between the blood remaining in the blood vessel and the inner lining of the blood vessel. This state could be confirmed by the above confirmation work.

Although α-cyanoacrylate is used as the adhesive in the above description, the present invention is not limited to the above α-cyanoacrylate as the adhesive, and the performance as the above-mentioned adhesive is not limited. Any can be used as long as it has

For example, a liquid monomer such as bone cement, which is currently used as a bio-adhesive, gelatin-
A mixed adhesive of resinozole-formaldehyde or a bioadhesive of an aqueous polymer solution such as fibrin glue or collagen glue can be used.

[Second Example of Embodiment of the Invention] Further, in the above-described first example, the second balloon 30 has a structure in which the adhesive exudes from the micropores. Therefore, due to the property of α-cyanoacrylate that it rapidly solidifies in the presence of water, a drying operation was inevitably used during actual use. Then, when negative pressure is applied to the injection cavity of the catheter, water enters the injection cavity and the filled α
There was a risk that the cyanoacrylate would harden in the injection cavity. As a result, the operation of applying negative pressure to the injection cavity in blood or water is contraindicated.

Considering the above points, the second balloon 3
The above-mentioned point can be eliminated by configuring 0 as a permeation membrane in one direction in which moisture does not permeate into the inside from the outer wall and moisture and a drug permeate from the inside. As the one-way permeable membrane, a material for an artificial organ or the like can be used [Third example of embodiment of the invention] As described above, the injection amount of an adhesive suitable for forming a tunnel in a blood vessel wall is Only about 0.04 ml was suitable, but this amount is almost the same as the volume of the tunnel wall itself having a wall thickness of 0.2 mm, an inner diameter of 3.0 mm and a major axis length of 2 cm. However, since the value is very small, it requires some skill to adjust the injection amount.

In view of the above points, the injection amount can be set by the adhesive holding portion 40 so that the injection amount of the adhesive agent into the catheter can be set more accurately and more easily. A third example of the embodiment of the present invention configured to automatically inject only the adhesive will be described below.

In a third example of an embodiment of the invention,
It is possible to set the adhesive injection amount of the holding adhesive in the adhesive holding part,
The adhesive injection amount is set automatically so that the set amount can be automatically injected. An example of an embodiment of the invention according to the present invention configured in this way is shown in FIG.

FIG. 4 is a block diagram showing the construction of the injection amount control unit and the expansion pressure control unit of the catheter of the third example.

In FIG. 4, 100 is a control unit for controlling the whole, 110 is an input unit for inputting various instructions, an operation guidance by the input unit, a display unit capable of notifying the input result, the control result in the control unit 110, and the like. An operation unit provided, 120 is a therapeutic agent holding unit that holds a therapeutic agent such as an adhesive, 130 is a control valve for the therapeutic agent that controls whether or not to inject the therapeutic agent into the catheter, and 140 is an injection amount of the therapeutic agent. A flow rate detection unit 150 for detection is a pressurizing unit for the therapeutic agent that applies a predetermined pressure to the therapeutic agent in the therapeutic agent holding unit 120.

Further, 160 is an expansion material holding portion for holding the expansion material, 170 is a control valve for the expansion material for controlling whether or not to inject the expansion material into the catheter, and 180 is a pressure detection portion, which is inside the catheter. A pressure detection unit 190 for detecting the pressure in the catheter accompanying the injection of the expansion material, 190 applies a predetermined pressure to the expansion material in the expansion material holding unit 160, presses the expansion material into the catheter at a predetermined pressure, and operates the operation unit in the catheter. It is a pressure control unit that applies the pressure set at 110 and applies a negative pressure after the treatment to store the expansion material in the catheter in the expansion material holding unit 160.

Reference numeral 200 denotes the base of the catheter,
Reference numeral 210 denotes the first balloon 20 and the second balloon 20 shown in FIGS.
1 is a therapeutic agent injection port connected to the injection cavity of the balloon 30, and 220 is an expansion material injection port connected to the injection cavity in the first balloon 20 shown in FIGS.

In the third example having the above configuration,
First, a guidance for setting input is displayed on the display unit of the operation unit 110, and according to this guidance, the expansion material is injected into the catheter to input the expansion pressure value for the balloon, and subsequently the time for applying pressure is set and input. To do. At the same time, the start time of injection of the expansion material and the injection of the therapeutic agent are designated and input, and the injection amount is set and input together.

After that, the expansion duration by the expansion material is set and the input of the control instruction is completed. The above setting is performed before operating the catheter, and a necessary amount of the therapeutic agent is put into the therapeutic agent holding unit 120 before operating the catheter, and the necessary amount of expansion is held in the expansion material holding unit 160. Add the ingredients.

Then, by operating the catheter, the tip of the catheter is inserted and positioned in the target expansion portion in the blood vessel to be treated.

Then, an instruction to start the treatment is input from the operation unit 100. As a result, the controller 100 causes the flow rate detector 140 to operate.
Is started to start detecting the injection amount of the adhesive, which is the therapeutic agent, from the injection port 210. Subsequently, the control valve 130 is opened to allow injection of the therapeutic agent, and the pressurizing unit 150 is driven to inject the therapeutic agent from the injection port 21 between the first balloon 20 and the second balloon 30 at the catheter tip. inject. When the injection of the set amount is completed, the control valve 130 is closed and the pressurizing unit 150 is stopped.

Since the injection amount of the therapeutic agent is displayed on the display during the injection, if the injection amount can be confirmed and the injection of the therapeutic agent can be stopped depending on the treatment situation, the operation unit is operated. By manipulating 110, the infusion of therapeutic agent can be stopped at any time.

In addition to the above control, the control unit 100 also controls the expansion of the first balloon 20. The pressure control unit 190 is controlled and driven in a pressurized state, and the control valve 1
Open 70 and allow infusion of dilating material into the first balloon 20 of the catheter tip. At the same time, the pressure detection unit 180 is driven to detect the expansion pressure inside the catheter. The expansion material is injected into the first balloon 20 according to the pressurization of the pressure control unit 190, and the expansion pressure rises. Therefore, the control unit 100 has the pressure detection unit 180.
Monitor the detected pressure value and wait until the set pressure value is reached.

When the pressure reaches the predetermined pressure value, the pressure control unit 190 is stopped and the control valve 170 is closed so that the expansion pressure inside maintains the set value. When the expansion pressure is changed with a fixed time, the control valve is opened to return the inside expansion material to the inside of the expansion material holding section 160, or the control valve 170 is opened to drive the pressure control section 190 to further expand the expansion pressure. Control to raise or lower.

When the pressurization for the set time is completed, the control valve 170 is opened and the pressure control unit 190 is controlled to apply a negative pressure to take out the expansion material from the catheter and store it in the expansion material holding unit 160. . Then, when the storage of the expansion material is completed, the control by the series of control units 100 is completed.

After that, the catheter is taken out of the living body and the treatment is terminated. As described above, according to the third example, the injection amount of the adhesive can be accurately controlled.
Reliable treatment can be performed.

[Fourth Example of Embodiment of the Invention] In the above examples, the therapeutic agent was injected after the catheter reached the target dilation site, but the present invention is limited to the above examples. However, if the therapeutic agent is stored in advance between the first balloon 20 and the second balloon 30 and the first balloon 20 is inserted into the blood vessel in a contracted state, The therapeutic agent does not exude to the outside. A fourth example according to the present invention focusing on this point will be described below.

In the fourth example, the first balloon 20
An optimal amount of the therapeutic agent is previously stored between the second balloon 30 and the second balloon 30. Then, the catheter containing the therapeutic agent therein is positioned at the target expansion site.

Then, the expansion material is injected into the first balloon 20 and expansion pressure is applied. As a result, the first balloon 20 expands, and the expansion pressure of the first balloon 20 applies pressure to the therapeutic agent between the second balloon 30 and the therapeutic agent. As a result, the therapeutic agent oozes out from the micropores of the second balloon 30 and instantly hardens the fragile blood vessel wall, which easily collapses, together with the lesion, and reinforces it in a tunnel shape.

[Fifth Example of Embodiment of the Invention] In the above description, the first balloon 20 and the second balloon 30 are described.
Both are shaped to expand by the expansion pressure of the expansion material or by the injection pressure of the injection adhesive. Therefore, the second
The application area is generally proportional to the amount of the adhesive that oozes out from the balloon 30. Therefore, if the error in the amount of adhesive is large, the error in the coating area will also be large.

Therefore, it is necessary to pay close attention to the injection amount of the adhesive, and even if the amount of the adhesive is the same, the application place may not be constant or the application area may be different. there were. The fifth example has been made in view of the above points, and the second and third aspects are provided so that the place and the area to which the adhesive is applied can be made constant even if the amount of the adhesive changes a little.
The fifth example of the embodiment of the present invention according to the present invention will be described below in which the shape of the balloon when expanded is configured such that the medicine exuded from the inside exudes only to a predetermined area.

The configuration of the blood vessel catheter of the fifth example is shown in FIG.
Shown in In FIG. 5, the configurations and shapes of the catheter body 10 and the first balloon 20 are the same as the configurations shown in FIG. 1 described above, but in the fifth example, the shapes of the second balloons are different. That is, in FIG. 5, the second balloon 530 has an elongated shape, and the front and rear of the second balloon 530 are configured to have a shape (black arrow) protruding like a gentle hill when expanded. .

With the above structure, the adhesive 500 exuded from the inside when the second balloon 530 is expanded.
Is contained in the slightly depressed portion of the second balloon 530, and the exuding adhesive does not get over the hill portion and diffuse, so that the adhesive layer is easily formed only in the intended range. You can do it.

The catheter of the fifth example is the second one as described above.
The drug exuded from the balloon 530 can be applied only within a certain range. For this reason,
It is not limited to the above-mentioned application in the case of applying in the blood vessel at the time of adhesion, and any drug can be used for administration. For example, it is possible to reliably administer the therapeutic agent to a site requiring treatment of the blood vessel wall, such as administering an anti-inflammatory agent to the site where the blood vessel wall is inflamed, and even in this case, it is unnecessary. It is possible to provide an easy-to-use intravascular catheter in which the therapeutic agent does not diffuse to the site.

As described above, according to the intravascular catheter of the fifth example, it is possible to apply or administer the therapeutic agent only to a desired site in the blood vessel without being affected to some extent by the therapeutic agent. It is possible to improve the therapeutic effect. Further, as this therapeutic agent, there are (1) thrombolytic agents, (2) agents for preventing stenosis of blood vessel wall, (3) gene therapeutic agents including agents for preventing vascular regrowth, and all other agents. It can be used for application or administration.

[Other Examples of Embodiments of the Invention] In the above description, the blood vessel contrast agent was used as the expansion material, but the present invention is not limited to the above examples, and various materials can be used. Can be used.

The most suitable expansion material is an angiographic agent, but any expansion material that does not adversely affect the living body, such as physiological saline, can be used.

As described above, according to the present invention, a therapeutic agent can be exuded to a desired site in a blood vessel, and an accurate treatment can be performed.

Further, by using a blood vessel wall coagulating agent as a therapeutic agent and reinforcing the blood vessel wall with the blood vessel wall coagulating agent, new coronary artery reconstruction can be performed.

Furthermore, the shape of the expanded second balloon is
When the front and rear sides are made to project like a gentle hill when expanded, it is possible to administer the drug only to a desired portion, and to reliably and easily enhance the therapeutic effect.

[0068]

[Brief description of drawings]

FIG. 1 is a diagram showing a state before expansion of an intravascular catheter according to an example of an embodiment of the present invention.

FIG. 2 is a diagram showing a state after expansion of the intravascular catheter according to the embodiment of the present invention.

FIG. 3 is a schematic diagram for explaining coronary artery reconstruction with the catheter of this example.

FIG. 4 is a diagram showing a second example of the embodiment of the present invention according to the present invention.

FIG. 5 is a diagram showing a fifth example of the embodiment of the present invention according to the present invention.

[Explanation of symbols]

 20 1st balloon 30, 530 2nd balloon 40 Adhesive holding part 50 Expansion pressurizing part 100 Control part 110 Operating part 120 Therapeutic agent holding part 130 Control valve for therapeutic agent 140 Flow rate detecting part 150 Pressurizing part 160 Expansion material holding section 170 Control valve for expansion material 180 Pressure detection section, 190 Pressure control section 200, 500 Therapeutic agent 210 The injection port of the therapeutic agent 220 The injection port of the expansion material

Claims (8)

[Claims] 1. A first balloon capable of injecting a dilating material for dilating a blood vessel into the vicinity of a distal end portion of an intravascular catheter to be inserted into a blood vessel of a living body, and at least a part of the first balloon. The first on the outer periphery
A second balloon having at least a part of an outer wall capable of injecting or holding a coagulant having an antithrombotic property that reinforces the blood vessel wall between the balloon and the outer wall permeable to the outside, The intravascular catheter, wherein the first balloon and the second balloon are made of a synthetic resin that does not react with the coagulant. 2. The intravascular catheter according to claim 1, wherein the second balloon is formed of an osmotic membrane having a unidirectional permeation characteristic from the inner side to the outer side. 3. A coagulant is preliminarily held in a liquid-tight state between the first balloon and the second balloon, and the first balloon is treated at the treatment site.
The intravascular catheter according to claim 1 or 2, wherein when the balloon is expanded, a coagulant is permeated to the outside from the second balloon to reinforce the inner wall of the blood vessel. 4. The blood vessel according to claim 1, wherein the second balloon is pressurized by the expansion of the first balloon to allow the coagulant to penetrate into the blood vessel. Inner catheter. 5. The first balloon has an elongated shape,
The intravascular catheter according to any one of claims 1 to 4, wherein the front and rear sides are shaped like a gentle hill when they are expanded. 6. A first balloon capable of injecting a dilating material for dilating a blood vessel into a distal end portion of an intravascular catheter to be inserted into a blood vessel of a living body, and at least a part of an outer circumference of the first balloon. Part 1 above
A second balloon having at least a part of an outer wall capable of injecting or holding the therapeutic agent with the balloon and holding the retained therapeutic agent into the outside, wherein the second balloon has an elongated shape. An intravascular catheter characterized in that the front and the rear have a shape that gently bulges when expanded. 7. The intravascular catheter according to claim 6, wherein the second balloon is formed of a permeable membrane having a one-way permeable property from the inside to the outside. 8. A therapeutic agent is preliminarily held in a liquid-tight state between the first balloon and the second balloon, and the first agent is treated at the treatment site.
The treatment is performed by causing the therapeutic agent to penetrate into the inner portion of the second balloon, which has a hump-like shape, by being pressurized by the expansion of the first balloon when the second balloon expands. The intravascular catheter according to claim 6 or 7.